Drug Profile

SIM 0686

Alternative Names: SIM-0686

Latest Information Update: 28 Jul 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Simcere Zaiming
Developer Jiangsu Simcere Pharmaceutical; Simcere Zaiming
Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
Mechanism of Action DNA topoisomerase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes - Solid tumours

Highest Development Phases

Phase I Solid tumours

Most Recent Events

21 Jul 2025 The US FDA approves IND application for SIM 0686 in Solid tumours in USA
21 Jul 2025 Simcere Zaiming plans a clinical trial in Solid tumours (Late stage disease, Metastatic disease) in USA (Parenteral)
09 Jul 2025 SIM 0686 is available for licensing as of 09 Jul 2025. https://en.simcere.com/kfhz/kfhz.aspx#hz01

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com